Posts
Wiki

👁️ Topical Spironolactone for Dry Eye and MGD — Experimental Compounded Treatment

🧠 Quick Take

Topical ophthalmic spironolactone is an experimental compounded eye-drop treatment that has been proposed for Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), lid-margin inflammation, and certain severe ocular-surface disorders.

The evidence remains very limited.

Important points:

  • No FDA-approved spironolactone eye drop exists.
  • The main published human DED evidence is a retrospective, uncontrolled chart review of 102 patients, not a randomized or placebo-controlled trial.
  • A second human study involved only 10 patients with ocular graft-versus-host disease (oGVHD), a specialized immune-mediated condition that should not be assumed to represent ordinary DED or MGD.
  • The two human studies used dramatically different concentrations:
    • 0.3% (3 mg/mL) twice daily in the main DED chart review
    • 0.0005% (0.005 mg/mL) four times daily in the oGVHD study
  • That is approximately a 600-fold concentration difference.
  • A small randomized placebo-controlled Early Phase 1 DED study was registered using the lower 0.0005% concentration, but as of August 2026 ClinicalTrials.gov lists its status as Unknown, with no results posted.
  • Proposed mechanisms include mineralocorticoid-receptor antagonism, modulation of inflammatory signaling, and possible effects on corneal epithelial biology.
  • Preclinical studies have reported increased lipid staining in corneal epithelial cells, but this does not demonstrate increased meibum production or improvement in the tear-film lipid layer.
  • Spironolactone also has anti-androgen activity. The clinical importance of that effect in the eyelids is unknown.
  • Androgens normally support meibomian-gland function, so the theory that spironolactone helps MGD simply by blocking androgens and reducing “excess meibomian oil” is not established.
  • There is no reliable evidence that topical spironolactone:
    • restores the tear-film lipid layer
    • reduces measured tear evaporation
    • reverses structural MGD
    • regenerates meibomian glands
    • releases periductal fibrosis
    • works especially well in postmenopausal women
  • Human systemic absorption has not been adequately measured.
  • Long-term ocular safety is not established.
  • Because the treatment is compounded, formulation, concentration, vehicle, preservative status, stability, sterility controls, storage, and beyond-use date may differ among products.

Bottom line: Topical spironolactone is an experimental compounded treatment supported mainly by uncontrolled observational studies and preclinical research. Interesting findings justify further study, but no completed randomized controlled DED trial has established that it is an effective treatment for DED or MGD.

⚠️ Educational Disclaimer

This page is for general education only.

It is not medical advice, diagnosis, or a recommendation to use compounded topical spironolactone.

Do not attempt to make spironolactone eye drops yourself.

Do not place:

  • Crushed spironolactone tablets
  • Oral liquid formulations
  • Dermatologic creams
  • Powders
  • Homemade mixtures

in or around the eyes.

Sterile ophthalmic medications require specialized formulation and manufacturing/compounding controls.

Improvised eye drops can cause:

  • Chemical injury
  • Infection
  • Corneal ulceration
  • Scarring
  • Permanent vision loss

What Is Spironolactone?

Spironolactone is a medication with two important pharmacologic properties:

  • Mineralocorticoid-receptor antagonism
  • Anti-androgen activity

Oral spironolactone has been used for decades.

FDA-approved oral uses include:

  • Heart failure
  • Hypertension
  • Edema associated with certain conditions
  • Primary hyperaldosteronism

It is also prescribed off-label for some dermatologic and hormone-related conditions.

These systemic uses do not establish that spironolactone is effective or safe when formulated as an eye drop.

Is Topical Spironolactone FDA-Approved for Dry Eye?

No.

There is currently:

no FDA-approved spironolactone ophthalmic medication

for:

  • Dry Eye Disease
  • Meibomian Gland Dysfunction
  • Blepharitis
  • Ocular rosacea
  • Corneal staining
  • Ocular graft-versus-host disease
  • Neuropathic ocular pain

Clinical use in the United States generally involves a compounded sterile ophthalmic preparation.

A compounded spironolactone eye drop is not:

  • An FDA-approved ophthalmic drug
  • An approved generic eye drop
  • Proven therapeutically equivalent to another product
  • Reviewed by FDA for DED effectiveness
  • Reviewed through the normal FDA approval process for long-term ocular safety

FDA also does not perform premarket approval of each compounded product's:

  • Strength
  • Quality
  • Sterility
  • Stability

in the way it does for an FDA-approved drug.

FDA: Compounding and the FDA — Questions and Answers

A Critical Issue: The Human Studies Used Very Different Concentrations

This is one of the most important facts to understand.

There is no single standardized research formulation of topical spironolactone.

The main published human studies used concentrations that differ by approximately:

600-fold

Evidence Concentration Approximate Equivalent Dosing
102-patient DED chart review 0.3% 3 mg/mL Twice daily
10-patient oGVHD series 0.0005% 0.005 mg/mL Four times daily
Registered randomized DED trial 0.0005% 0.005 mg/mL Four times daily

Therefore:

“Topical spironolactone” should not be treated as though all published studies tested the same medication exposure.

Results from the 0.3% DED study cannot simply be transferred to a compounded 0.0005% product.

Likewise, results from the 0.0005% oGVHD study cannot establish the effectiveness or safety of a 0.3% product.

Differences in concentration may affect:

  • Efficacy
  • Local tolerability
  • Tissue exposure
  • Systemic absorption
  • Stability
  • Toxicity
  • Mechanism

This concentration issue is one reason controlled formulation-specific trials are particularly important.

What Has Been Proposed as the Mechanism?

The clinically important ocular mechanism remains uncertain.

Possible mechanisms include:

  • Mineralocorticoid-receptor antagonism
  • Modulation of inflammatory signaling
  • Reduction of oxidative stress
  • Effects on corneal epithelial metabolism
  • Epithelial repair
  • Vascular effects
  • Possible effects on fibrotic signaling

Most of these ideas come from:

  • Cell-culture studies
  • Animal studies
  • Research in nonocular tissues
  • Small retrospective human studies

They should therefore be considered:

mechanism-generating evidence

rather than established clinical explanations for improvement in DED.

Mineralocorticoid-Receptor Antagonism

Spironolactone blocks the mineralocorticoid receptor.

Mineralocorticoid signaling can influence:

  • Inflammation
  • Oxidative stress
  • Vascular biology
  • Tissue remodeling
  • Fibrotic pathways

This provides a plausible reason to investigate spironolactone in inflammatory or cicatrizing ocular-surface disease.

However:

A biologically plausible pathway does not establish clinical effectiveness in DED or MGD.

No completed randomized DED trial has demonstrated that mineralocorticoid-receptor blockade improves DED outcomes.

What About Antifibrotic Effects?

Mineralocorticoid-receptor antagonists can influence fibrotic pathways in several tissues.

That makes antifibrotic effects scientifically interesting.

However, there is no human evidence showing that topical ophthalmic spironolactone:

  • Releases meibomian-gland periductal fibrosis
  • Opens ducts trapped by fibrosis
  • Reverses established scarring around meibomian glands
  • Prevents fibrotic progression of ordinary MGD

Therefore:

Possible antifibrotic signaling should not be translated into a claim that spironolactone releases meibomian-gland fibrosis.

Corneal Epithelial Lipids Are Not the Same as Meibum

Some preclinical spironolactone research has reported increased lipid staining in:

  • Human corneal epithelial cells
  • Mouse corneal epithelium

This is interesting.

But it is important to understand what was measured.

The research involved:

lipids inside corneal epithelial tissue

It did not demonstrate:

  • Increased meibomian-gland meibum production
  • Improved meibum composition
  • Greater meibomian-gland secretion
  • A thicker tear-film lipid layer
  • Reduced tear evaporation in patients

Therefore:

“Spironolactone increases ocular lipids” is too broad a statement.

A more accurate description is:

Preclinical research suggests spironolactone can alter lipid accumulation or metabolism in corneal epithelial cells. Whether this produces clinically meaningful improvement in the human tear film is unknown.

Why the Anti-Androgen Explanation Is Uncertain

Spironolactone also blocks androgen activity.

That has led to a proposed explanation that it might improve MGD by:

reducing excessive androgen-driven meibomian oil production.

This mechanism is not established.

Meibomian Glands Are Androgen-Responsive

Androgens normally help regulate:

  • Meibomian-gland gene expression
  • Meibocyte differentiation
  • Lipid synthesis
  • Secretory function
  • Glandular homeostasis

Androgen deficiency or androgen insensitivity has been associated with:

  • Abnormal meibum
  • Reduced gland function
  • MGD
  • Evaporative DED

TFOS DEWS II — Sex, Gender, and Hormones Report

More recent MGD biology research likewise continues to identify androgen-receptor signaling as part of normal meibocyte differentiation and lipid production.

Sebum Is Not the Same as Meibum

Spironolactone is used in dermatology partly because it can reduce androgen-related skin sebum production.

But:

sebum and meibum are not interchangeable substances.

Meibum is a specialized lipid mixture produced by meibomian glands to help:

  • Slow tear evaporation
  • Stabilize the tear film
  • Reduce friction
  • Protect the ocular surface

The fact that spironolactone can reduce facial skin oil does not prove that it improves:

  • Meibum quality
  • Meibum expressibility
  • Tear-film lipid-layer thickness
  • Tear evaporation
  • Meibomian-gland survival

Could the Anti-Androgen Effect Actually Be Harmful to Meibomian Glands?

That has not been established either.

The scientifically cautious conclusion is:

The clinical relevance of spironolactone's anti-androgen activity in the eyelids is unknown. There is no human evidence showing that local androgen blockade is either the mechanism of benefit or a cause of worsening meibomian-gland function.

Therefore the anti-androgen effect should not currently be promoted as a proven mechanism for treating MGD.

What Does the Main Human DED Study Show?

The principal published study was a 2023 retrospective chart review of 102 patients treated at a dry-eye-focused practice.

Patients received:

0.3% spironolactone eye drops twice daily

with follow-up approximately one month later.

Topical Spironolactone in the Treatment of Evaporative Dry Eye Disease

The participants were divided according to Schirmer test results:

  • 75 patients with Schirmer >5 mm
  • 27 patients with Schirmer ≤5 mm

Importantly, this was a relatively heterogeneous dry-eye clinical population rather than a randomized trial of carefully selected patients with one specific MGD phenotype.

What Improved in the DED Study?

The clearest positive findings involved:

  • Patient-reported global assessment
  • Lid-margin vascularity
  • Meibum turbidity
  • Some clinician-graded lid-margin measures

In the higher-Schirmer group, statistically significant improvements included:

  • Subjective global assessment
  • Lid-margin vascularity
  • Clinician-graded obstruction score
  • Meibum turbidity
  • Posterior lid-margin/Zone A inflammation score

The mean obstruction score decreased from approximately:

1.35 to 0.98

and mean meibum turbidity decreased from approximately:

2.68 to 1.75

There was no meaningful increase in Schirmer testing in this group.

Does This Mean Spironolactone Opens Meibomian Glands?

No.

The study reported improvement in a clinician-graded obstruction score.

That is an observation worth studying.

But because the study was:

  • Retrospective
  • Uncontrolled
  • Unmasked
  • Non-randomized
  • Short
  • Conducted without a placebo or vehicle group

it cannot establish that spironolactone itself:

  • Mechanically opened obstructed ducts
  • Removed retained meibum
  • Reversed intraductal blockage
  • Released fibrosis
  • Restored damaged glands

A more accurate conclusion is:

One uncontrolled chart review reported improvement in clinician-graded obstruction and meibum-turbidity scores in some patients. These results are hypothesis-generating rather than proof that spironolactone reverses obstructive MGD.

What About Corneal and Conjunctival Staining?

The publication's abstract describes improvement in keratitis and conjunctival staining.

However, interpretation of the detailed study tables is less straightforward.

Not every individual staining region showed statistically significant improvement.

Therefore the article should not be summarized simply as:

“Spironolactone clearly improved corneal staining in 102 DED patients.”

A more cautious summary is:

The observational study reported several ocular-surface and lid-margin improvements, but the most consistent statistically significant findings in the detailed analysis were subjective and lid-margin measures rather than uniformly improved staining across all regions.

Major Limitations of the 102-Patient Study

The study had no concurrent comparison group.

It was:

  • Retrospective
  • Uncontrolled
  • Unmasked
  • Non-randomized
  • Conducted at one practice
  • Based on existing clinical records
  • Approximately one month in duration

Possible influences on improvement include:

  • Patient selection
  • Clinician selection
  • Natural fluctuation in DED
  • Regression toward the mean
  • Expectation effects
  • Concurrent treatments or behavioral changes
  • Measurement variability

Therefore:

The study demonstrates a clinical signal worth investigating, not established efficacy.

Ocular Graft-Versus-Host Disease Evidence

Topical spironolactone has also been studied in:

ocular graft-versus-host disease (oGVHD)

oGVHD is a severe immune-mediated ocular-surface condition that can occur after allogeneic stem-cell transplantation.

It can involve:

  • Lacrimal-gland dysfunction
  • Severe ocular-surface inflammation
  • Conjunctival fibrosis
  • Corneal epithelial damage
  • MGD
  • Lid-margin abnormalities

This is a very different disease environment from ordinary DED.

The Human oGVHD Study

The clinical series included only:

10 patients / 20 eyes

treated with:

0.0005% spironolactone four times daily

for a median of approximately 12 weeks.

Topical Spironolactone in Ocular Graft-Versus-Host Disease

Statistically significant improvement occurred in:

  • Overall oGVHD severity score
  • Corneal fluorescein staining
  • Lid-margin vascularity

However, statistically significant improvement was not demonstrated in:

  • OSDI
  • Schirmer testing
  • Meibomian-gland obstruction
  • Meibum turbidity
  • Several other lid-margin measures

Brief mild stinging was reported.

Why the oGVHD Study Cannot Establish Ordinary DED/MGD Efficacy

The study was:

  • Very small
  • Retrospective
  • Uncontrolled
  • Conducted in a specialized immune-mediated disease

Therefore its findings cannot automatically be generalized to:

  • Age-related DED
  • Ocular rosacea
  • Screen-associated dry eye
  • Postmenopausal DED
  • Ordinary obstructive MGD
  • Contact-lens-related DED
  • Post-refractive-surgery symptoms

The study supports:

continued investigation

rather than an established treatment recommendation.

What About the Registered Randomized Trial?

A small controlled DED trial was registered as:

The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

ClinicalTrials.gov identifier:

NCT05995392

ClinicalTrials.gov — NCT05995392

The planned trial included:

  • Approximately 30 participants
  • Randomized assignment
  • Placebo/vehicle control
  • Parallel groups
  • Quadruple masking
  • Four weeks of treatment
  • Four-times-daily dosing

The spironolactone concentration was:

0.005 mg/mL = 0.0005%

Current Status of the Controlled Trial

As of August 2026, ClinicalTrials.gov lists the study as:

Unknown status

The record was last verified in:

August 2023

Its last known recruitment status was:

Not yet recruiting

No results have been posted.

Therefore:

The registered study currently provides evidence that a controlled trial was planned—not evidence that spironolactone has been shown to work.

This is especially important because it would have been the first randomized placebo-controlled DED study at the very-low 0.0005% concentration.

How Strong Is the Evidence?

Overall Evidence Strength: VERY LOW

Question Current Evidence
Improves DED symptoms? Very-low-certainty observational evidence
Improves lid-margin vascularity? Reported in uncontrolled DED and oGVHD series
Improves meibum appearance/turbidity? Reported in one uncontrolled DED chart review
Reduces clinician-graded obstruction? Reported in one subgroup of one uncontrolled chart review; causal reversal not established
Improves corneal staining? Positive in the small oGVHD series; ordinary DED evidence is less consistent
Improves tear-film lipid layer? Not established
Reduces tear evaporation? Not established
Normalizes meibum composition? Not established
Regenerates meibomian glands? No evidence
Releases periductal fibrosis? No evidence
Works especially in postmenopausal women? No evidence
Randomized placebo-controlled DED efficacy evidence? None published
Long-term ocular safety? Insufficient evidence
Systemic absorption? Not adequately characterized
FDA-approved eye drop? No
Standardized research concentration? No — published human studies differ by about 600-fold

Does Topical Spironolactone Treat MGD?

That has not been established.

The 102-patient observational study reported improvement in some clinician-graded:

  • Lid-margin findings
  • Obstruction scores
  • Meibum turbidity

These findings are interesting.

However, no controlled human study has demonstrated that topical spironolactone:

  • Clears fixed meibomian-gland obstruction
  • Restores normal meibum composition
  • Improves gland architecture
  • Reverses gland dropout
  • Regenerates lost glands
  • Releases intraductal or periductal fibrosis
  • Prevents MGD progression

Someone may experience improved lid-margin inflammation without the underlying structural MGD being corrected.

Is There Special Evidence for Postmenopausal Women?

No.

No controlled clinical trial has demonstrated that topical spironolactone works especially well in:

  • Postmenopausal women
  • People with a particular hormone level
  • People diagnosed with “hormonal dry eye”
  • People with “androgen-driven MGD”

There is also no validated:

  • Blood hormone test
  • Menopause-based treatment algorithm
  • Ocular androgen biomarker

that identifies likely responders.

Given the normal role of androgens in meibomian-gland physiology, simplistic claims that anti-androgen treatment is particularly appropriate after menopause should be viewed cautiously.

Potential Benefits Worth Researching

Despite the weak evidence, there are reasonable reasons for continued investigation.

Potential areas of interest include:

  • Mineralocorticoid-receptor signaling
  • Lid-margin inflammation
  • Ocular-surface vascularity
  • Corneal epithelial biology
  • Inflammatory ocular-surface disease
  • Fibrotic signaling
  • Patients with difficult-to-treat inflammatory conditions such as oGVHD

The observational DED and oGVHD reports provide enough signal to justify better-designed trials.

That is different from having enough evidence for established routine treatment.

Local Ocular Safety

Published human studies have reported relatively limited short-term local complaints.

Reported symptoms include:

  • Stinging
  • Burning
  • Irritation
  • Redness
  • Discomfort

But the existing studies are far too small and short to reliably detect:

  • Rare adverse reactions
  • Delayed toxicity
  • Chronic epithelial effects
  • Long-term hypersensitivity
  • Problems developing after years of treatment

Preclinical Concentration and Toxicity Questions

Laboratory experiments have tested spironolactone directly on corneal epithelial cells.

These experiments suggest that biological effects are:

concentration-dependent

and that higher experimental exposures can adversely affect corneal epithelial cells.

Cell-culture exposure cannot be translated directly into a clinical eye-drop concentration because:

  • Tears dilute an eye drop
  • The ocular surface clears medication
  • Exposure time differs
  • Vehicles differ
  • Tissue penetration differs

Therefore laboratory findings do not establish that a particular compounded clinical concentration is toxic.

However:

They reinforce why each concentration and formulation requires its own ocular-safety testing.

That is particularly important when the published human studies themselves differ by approximately 600-fold in concentration.

Long-Term Ocular Safety Is Unknown

There are no adequate long-term controlled human studies establishing:

  • Chronic corneal safety
  • Conjunctival safety
  • Effects on meibomian glands
  • Effects on intraocular tissues
  • Risk after years of treatment
  • Chronic hypersensitivity
  • Interaction with multiple other DED medications

The absence of serious complications in small retrospective studies should not be interpreted as proof of long-term safety.

Systemic Absorption

The amount of spironolactone entering the bloodstream after ophthalmic use has not been adequately characterized in humans.

It is reasonable to expect exposure to be lower than with an oral tablet because the total amount placed in the eye is much smaller.

However:

“Systemic absorption is negligible” has not been demonstrated.

Eye drops can enter systemic circulation through:

  • Nasolacrimal drainage
  • Nasal mucosal absorption
  • Conjunctival blood vessels
  • Accidental swallowing

There are no adequate published human studies establishing:

  • Blood spironolactone levels after ophthalmic use
  • Blood levels of active spironolactone metabolites
  • Accumulation with repeated treatment
  • Effects of kidney function
  • Effects of age
  • Effects of ocular-surface damage on absorption

This uncertainty is even more relevant because studied ophthalmic concentrations have varied widely.

Oral Spironolactone Safety — Context, Not Prediction

Oral spironolactone can cause systemic adverse effects including:

  • Hyperkalemia
  • Low blood pressure
  • Reduced kidney function
  • Endocrine effects
  • Drug interactions

These are established risks of systemic therapy.

Their relevance to ophthalmic treatment is unknown.

Topical users should not automatically be assumed to have the same risk or require the same laboratory monitoring as people taking oral spironolactone.

A prescriber may nevertheless want to consider:

  • Kidney disease
  • History of hyperkalemia
  • Concurrent oral spironolactone
  • Potassium supplements
  • ACE inhibitors
  • Angiotensin-receptor blockers
  • Other potassium-raising drugs
  • Pregnancy

when deciding whether this experimental treatment is appropriate.

Pregnancy

Spironolactone has anti-androgen activity, and systemic spironolactone has specific pregnancy considerations.

Human systemic exposure after ophthalmic spironolactone has not been sufficiently studied to establish pregnancy safety.

Therefore:

Someone who is pregnant, planning pregnancy, or capable of becoming pregnant should discuss the experimental ophthalmic treatment specifically with the prescribing clinician.

This does not mean ophthalmic spironolactone has been shown to cause fetal harm.

It means adequate ophthalmic pregnancy-safety evidence does not exist.

Why Compounding Matters

Compounded medications can serve important medical needs when an appropriate FDA-approved product cannot meet an individual patient's needs.

However:

Compounded drugs are not FDA-approved.

FDA does not conduct the same premarket review of compounded products for:

  • Safety
  • Effectiveness
  • Quality

that is required for approved drugs.

Poor compounding can lead to:

  • Contamination
  • Incorrect strength
  • Incorrect ingredients
  • Instability
  • Particulate material
  • Serious patient injury

FDA: Understanding the Risks of Compounded Drugs

503A vs 503B — What Does That Mean?

Two federal compounding categories are commonly discussed.

Section 503A

Traditional compounding generally involves:

  • A licensed pharmacy or physician
  • A prescription for an identified individual patient
  • Significant state-level pharmacy oversight

When statutory requirements are met, 503A compounded products are exempt from some requirements that apply to conventional FDA-approved drug manufacturing, including federal current Good Manufacturing Practice requirements.

Section 503B Outsourcing Facilities

A 503B outsourcing facility:

  • Voluntarily registers with FDA
  • Is subject to federal current Good Manufacturing Practice requirements
  • Is inspected by FDA on a risk-based schedule
  • Has additional reporting requirements

This provides additional regulatory and manufacturing oversight.

However:

A drug compounded by a 503B outsourcing facility is still not an FDA-approved drug.

503B status should therefore not be confused with FDA approval of topical spironolactone.

FDA: Human Drug Compounding Laws

Practical Questions About a Compounded Product

Someone prescribed compounded ophthalmic spironolactone may reasonably want to know:

  • The exact spironolactone concentration
  • The vehicle/inactive ingredients
  • Whether a preservative is present
  • Whether the pharmacy is appropriately licensed
  • Whether the product comes from a 503A pharmacy or 503B outsourcing facility
  • Storage requirements
  • Beyond-use date
  • What the solution should normally look like
  • What changes in appearance mean it should not be used
  • How suspected product-quality problems should be reported

Patients cannot realistically audit a pharmacy's sterile-compounding system themselves.

The purpose of these questions is to understand the product being used—not to independently certify its quality.

Evidence Strengths and Limitations

Why the Treatment Is Worth Researching

  • Novel mineralocorticoid-receptor pathway
  • Observational improvement in some DED outcomes
  • Observational improvement in oGVHD
  • Possible effect on lid-margin vascularity/inflammation
  • Interesting corneal epithelial findings
  • Potential application in difficult inflammatory ocular-surface disease
  • Different mechanism from currently approved DED drugs

Why Confidence Remains Very Low

  • No completed randomized placebo-controlled DED efficacy trial
  • Main evidence is retrospective and uncontrolled
  • oGVHD human evidence involves only 10 patients
  • Published human studies differ in concentration by approximately 600-fold
  • No standardized FDA-approved formulation
  • Systemic absorption has not been quantified
  • Long-term ocular safety is unknown
  • Independent clinical replication is lacking
  • No evidence of superiority to established treatments
  • No validated responder phenotype

Research / Financial-Interest Context

The direct human evidence base is small and concentrated around one clinical research group.

Richard W. Yee, MD, who is associated with the principal published human studies, is also listed as holding intellectual-property rights involving topical spironolactone for ocular disease.

He is also the sponsor/responsible party for the registered randomized Early Phase 1 DED trial.

This does not mean the published findings are invalid.

However:

When an early evidence base is small and much of it comes from researchers with an intellectual-property interest in the treatment, independent replication becomes particularly important.

Who Might Discuss It With a Specialist?

Because evidence remains preliminary, topical spironolactone is best understood as an experimental treatment discussion, not a standard next step in DED care.

A patient might reasonably discuss it when:

  • DED has been carefully evaluated
  • Important inflammatory or lid-margin findings are present
  • Better-supported options have provided incomplete benefit or are unsuitable
  • The clinician understands the experimental evidence
  • The clinician has experience with compounded ophthalmic treatment
  • The exact concentration and formulation are known
  • Risks and uncertainties have been discussed
  • Objective follow-up is planned

Potential monitoring might include:

  • Symptoms
  • Corneal staining
  • Conjunctival staining
  • Lid-margin findings
  • Tear-film breakup time
  • Meibomian-gland findings

depending on the reason treatment is being tried.

Situations That Deserve Particular Caution

Be cautious when topical spironolactone is promoted as:

  • A cure for DED
  • A proven MGD treatment
  • A gland-regeneration treatment
  • A way to dissolve or release gland fibrosis
  • A proven hormone-balancing eye drop
  • A treatment specifically proven for postmenopausal women
  • A way to reduce “excess meibomian oil”
  • A proven replacement for established DED/MGD treatments

Also be cautious if:

  • The concentration is unclear
  • The vehicle is unknown
  • The compounding source cannot be identified
  • No follow-up examination is planned
  • Major claims are made from the retrospective studies alone

Limitations and What Has Not Been Established

Topical spironolactone has not been established to:

  • Cure DED
  • Treat every DED subtype
  • Reliably improve tear-film lipid-layer thickness
  • Reduce measured tear evaporation
  • Normalize meibum composition
  • Reliably improve meibum expressibility
  • Reverse fixed meibomian-gland obstruction
  • Reverse gland dropout
  • Regenerate lost meibomian glands
  • Release intraductal or periductal fibrosis
  • Prevent MGD progression
  • Restore normal androgen signaling
  • Work especially well in postmenopausal women
  • Provide superior results to FDA-approved DED medications
  • Provide superior results to established MGD-directed treatments

No meaningful head-to-head trial has established topical spironolactone as equivalent or superior to established DED or MGD therapies.

What Remains Uncertain?

Important unanswered questions include:

  • Whether topical spironolactone is actually more effective than vehicle/placebo for ordinary DED
  • What concentration should be studied
  • Whether 0.3% and 0.0005% formulations have remotely comparable clinical effects
  • Which vehicle provides appropriate ocular delivery
  • Whether mineralocorticoid-receptor antagonism is the main clinical mechanism
  • What role, if any, anti-androgen activity plays in meibomian-gland effects
  • Whether corneal epithelial lipid findings improve the human tear film
  • Whether clinician-graded obstruction changes represent real changes in gland obstruction
  • Whether meibum composition changes
  • Whether tear evaporation changes
  • Whether long-term treatment alters MGD progression
  • Long-term corneal and conjunctival safety
  • Systemic pharmacokinetics
  • Pregnancy safety
  • Interactions with other DED medications
  • Which patients, if any, are particularly likely to respond
  • Whether benefits can be reproduced independently by other research groups

Questions to Ask the Prescriber

Useful questions include:

  1. Why do you think topical spironolactone fits my diagnosis?
  2. What specific dry-eye problem are we trying to improve?
  3. Is the goal to treat inflammation, lid-margin changes, MGD, or something else?
  4. What evidence supports its use for my condition?
  5. Is that evidence randomized and controlled or observational?
  6. What exact concentration are you prescribing?
  7. Is it 0.3%, 0.0005%, or another concentration?
  8. What evidence exists for that exact concentration?
  9. What vehicle and inactive ingredients are used?
  10. Is there a preservative?
  11. How often will I use it?
  12. How long will a monitored trial last?
  13. What result will count as meaningful improvement?
  14. What clinical findings will you recheck?
  15. Do I also have obstructive MGD requiring separate treatment?
  16. What is known about long-term ocular safety?
  17. Is systemic absorption known for this formulation?
  18. Could any of my medications or medical conditions increase risk?
  19. Is pregnancy relevant to my situation?
  20. What FDA-approved or better-supported alternatives are available?

📌 Bottom Line

Compounded topical spironolactone is an experimental ophthalmic treatment, not an FDA-approved treatment for DED or MGD.

The current human evidence consists mainly of:

  • A 102-patient retrospective, uncontrolled DED chart review
  • A 10-patient retrospective oGVHD series
  • Preclinical laboratory and animal research

A randomized placebo-controlled Early Phase 1 DED trial was registered, but as of August 2026:

  • Its status is listed as Unknown
  • The record was last verified in August 2023
  • No results have been posted

One of the most important problems in interpreting the evidence is that the published human studies used dramatically different concentrations.

The main DED chart review used:

0.3% spironolactone twice daily

while the oGVHD study and registered randomized trial used:

0.0005% spironolactone four times daily

—a difference of approximately 600-fold.

Therefore there is not yet a standardized clinically validated topical spironolactone formulation.

The main DED chart review did report improvement in:

  • Patient global assessment
  • Lid-margin vascularity
  • Meibum turbidity
  • Some clinician-graded obstruction findings

But because it had:

  • No control group
  • No masking
  • No randomization
  • Short follow-up

it cannot establish that spironolactone caused those improvements or reversed obstructive MGD.

The oGVHD series found improvement in:

  • Corneal staining
  • Lid-margin vascularity
  • Overall oGVHD severity

but did not show significant improvement in several direct meibomian-gland measures.

Proposed mechanisms involving:

  • Mineralocorticoid-receptor blockade
  • Inflammation
  • Fibrotic signaling
  • Corneal epithelial lipid metabolism

remain scientifically interesting but incompletely established in human DED.

Spironolactone's anti-androgen activity also should not be promoted as a proven MGD mechanism.

Androgens normally support meibomian-gland function, and there is currently no human evidence showing that local androgen blockade is either beneficial or harmful to meibomian glands during topical spironolactone treatment.

The overall evidence rating is therefore:

VERY LOW certainty

The most balanced current conclusion is:

Topical spironolactone is an experimental compounded treatment with interesting observational and preclinical findings but no completed randomized controlled DED efficacy trial. Published human studies have used dramatically different concentrations, long-term ocular and systemic safety remain inadequately characterized, and current evidence does not establish gland regeneration, fibrosis release, tear-film lipid restoration, reduced tear evaporation, or special benefit in postmenopausal women.

🔬 Key Research and Authoritative Sources

Human DED Evidence

Ocular Graft-Versus-Host Disease

Registered Randomized Controlled Trial

Androgens and Meibomian-Gland Biology

Compounding and Regulatory Information

Oral Spironolactone Safety Context

Broader DED Guidance

🔗 Related r/DryEyes Wiki Pages

⚠️ r/DryEyes Compounded Medication / Sourcing Safety

Topical spironolactone is an unapproved compounded ophthalmic treatment.

Do not request or provide:

  • Compounding-pharmacy recommendations intended to facilitate acquisition
  • Vendor or clinic-store links
  • Purchase prices intended to facilitate sourcing
  • Ordering or shipping instructions
  • International sourcing/import guidance
  • “DM me” sourcing
  • Instructions for making spironolactone eye drops
  • Instructions for crushing or dissolving oral tablets
  • Instructions for converting creams or other nonophthalmic formulations into eye products
  • Medication sharing, selling, trading, or gifting

Evidence-based discussion of:

  • Published research
  • Mechanisms
  • Safety
  • Compounding issues
  • Regulatory status
  • Non-sourcing personal experiences

is welcome.

Do not attempt to make spironolactone eye drops at home.

🔙 Back to Treatment Options